Get the Daily Brief
Latest Biotech News
AbbVie ADC strategy scales with regulatory wins
Beyond the FDA clearance for Decnupaz, AbbVie’s broader antibody-drug conjugate strategy keeps delivering. Coverage noted that the BPDCN approval leverages Decnupaz’s lineage from AbbVie’s 2023...
Commercial coverage shift for Lilly’s oral and injectable obesity drugs
CVS Caremark changed its formulary positioning for Eli Lilly’s obesity portfolio, placing Foundayo (oral tirzepatide/GLP-1–based therapy per Lilly branding) on formularies June 1 and adding back...
Atopic dermatitis Phase 3 funding and deal mechanics
Apogee Therapeutics secured up to $1.3 billion in non-dilutive financing from Blackstone Life Sciences to fund Phase 3 development of zumilokibart (anti-IL-13) for moderate-to-severe atopic...
Eczema drug progress—Phase 2 signal behind Phase 3 push
Apogee’s zumilokibart continued to generate efficacy support as the biotech positioned for Phase 3. Reporting highlighted the company’s Part B 16-week APEX results, with outcomes used to bolster...
FDA device breakthrough designation for multi-cancer blood test
The FDA awarded Breakthrough Device Designation to Gene Solutions’ SPOT-MAS 10 multicancer early detection assay. The blood-based, adjunctive lab-developed test screens asymptomatic adults 40 and...
US coverage and regulatory pathway for cystic fibrosis prevention
Children’s Hospital Colorado pioneered prenatal therapy for cystic fibrosis, moving intervention earlier in life to target CF before birth. The approach was reported during Cystic Fibrosis...
Transplant diagnostics: pre-transplant kidney rejection risk signature
Verici Dx validated a pre-transplant kidney rejection risk test that aims to estimate early acute rejection risk before transplantation. The company’s Pre-Transplant Risk Assessment (PTRA)...
Precision and transparency in biopharma financials: ICON audit
An audit at ICON concluded the company overstated revenue by $65.3 million in 2023 and $92.7 million in 2024, according to the prompt text. The disclosure also referenced cash-raising activity...
Hepatitis B functional cure data and regulatory momentum
GSK and Ionis unveiled additional clinical data supporting bepirovirsen, a chronic hepatitis B therapy being pursued with a goal of achieving a “functional cure” in a subset of patients. The...
Non-dilutive funding and Phase 3 push for atopic dermatitis
Blackstone Life Sciences agreed to provide Apogee Therapeutics with up to $1.3 billion in non-dilutive financing to advance zumilokibart (zumi) into Phase III for moderate-to-severe atopic...
FDA device milestone for multiomic early cancer detection
The FDA awarded Breakthrough Device Designation to Gene Solutions’ SPOT-MAS 10, a blood-based multicancer early detection test. The adjunctive lab-developed assay is designed to screen...
Regulatory decision timing for AstraZeneca’s camizestrant breast cancer pill
The FDA delayed its decision on AstraZeneca’s oral SERD camizestrant after a negative advisory committee vote tied to issues including study design and the quality of evidence. The review...
Genetic regulator: Beren Therapeutics’ Niemann-Pick disease drug review delayed
The FDA pushed back its approval decision for Beren Therapeutics’ adrabetadex, extending the review after the company submitted major updates and clarifications. The decision date was originally...
FDA approval for ultra-rare blood cancer ADC after ImmunoGen acquisition
AbbVie said the FDA approved an antibody-drug conjugate (ADC) it obtained through its $10.1 billion buyout of ImmunoGen. The approval covers an ultra-rare but aggressive blood cancer indication,...
Clinical diagnostics tool expansion: Illumina’s MRD kit for oncology research
Illumina plans to launch a whole-genome sequencing measurable residual disease (MRD) detection kit in 2027. The research-use-only kit is intended to help more laboratories adopt MRD testing for...
Clinical-stage informatics: deep learning for post-radical nephrectomy risk stratification
Researchers introduced a multimodal deep learning model designed to predict functional prognostic risk in patients undergoing radical nephrectomy. The approach targets post-operative complication...
China gene editing funding: YolTech raises for CRISPR pipeline
China gene editing startup YolTech raised $70 million, its biggest funding round to date, as it pushes CRISPR therapies forward and looks toward an eventual Hong Kong IPO. The financing...
AI-targeting repositioned biotech: Verge Genomics rebrands after ALS trial failure
Verge Genomics rebranded as Verge Labs after reporting failure in an early clinical trial of VRG50635, an AI-designed experimental drug for ALS. The company said it laid off about 90% of staff as...
FDA decision delays and label scrutiny for breast cancer SERD
The FDA has delayed its decision on AstraZeneca’s oral SERD camizestrant after an advisory committee vote went against approval for a first-line setting in a subset of advanced breast cancer...
Regulatory breakthrough designation for multiomic blood cancer detection
Gene Solutions won US FDA Breakthrough Device Designation for SPOT-MAS 10, a multiomic early detection blood test aimed at asymptomatic adults. The assay combines machine-learning analysis of...